JP2023531869A5 - - Google Patents

Info

Publication number
JP2023531869A5
JP2023531869A5 JP2022571216A JP2022571216A JP2023531869A5 JP 2023531869 A5 JP2023531869 A5 JP 2023531869A5 JP 2022571216 A JP2022571216 A JP 2022571216A JP 2022571216 A JP2022571216 A JP 2022571216A JP 2023531869 A5 JP2023531869 A5 JP 2023531869A5
Authority
JP
Japan
Prior art keywords
tetramethyl
oxo
ions
oxazaphosfinan
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531869A (ja
Filing date
Publication date
Priority claimed from FR2005138A external-priority patent/FR3110393B1/fr
Application filed filed Critical
Publication of JP2023531869A publication Critical patent/JP2023531869A/ja
Publication of JP2023531869A5 publication Critical patent/JP2023531869A5/ja
Pending legal-status Critical Current

Links

JP2022571216A 2020-05-20 2021-05-20 神経保護を誘導するための化合物及び組成物 Pending JP2023531869A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR2005138A FR3110393B1 (fr) 2020-05-20 2020-05-20 Compose et composition pour induire une neuroprotection
FR2005138 2020-05-20
PCT/FR2021/050929 WO2021234324A1 (fr) 2020-05-20 2021-05-20 Compose et composition pour induire une neuroprotection

Publications (2)

Publication Number Publication Date
JP2023531869A JP2023531869A (ja) 2023-07-26
JP2023531869A5 true JP2023531869A5 (cg-RX-API-DMAC7.html) 2024-05-27

Family

ID=73013493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571216A Pending JP2023531869A (ja) 2020-05-20 2021-05-20 神経保護を誘導するための化合物及び組成物

Country Status (9)

Country Link
US (1) US12611387B2 (cg-RX-API-DMAC7.html)
EP (1) EP4142703B8 (cg-RX-API-DMAC7.html)
JP (1) JP2023531869A (cg-RX-API-DMAC7.html)
KR (1) KR20230013116A (cg-RX-API-DMAC7.html)
CN (1) CN116981449A (cg-RX-API-DMAC7.html)
CA (1) CA3178633A1 (cg-RX-API-DMAC7.html)
ES (1) ES2970378T3 (cg-RX-API-DMAC7.html)
FR (1) FR3110393B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021234324A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3149773B1 (fr) 2023-06-19 2026-04-17 Rest Therapeutics Nouvelles combinaisons synergiques a base de fenm
FR3163834A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine
WO2026003229A1 (fr) 2024-06-26 2026-01-02 Rest Therapeutics Derives de fluoroethylnormemantine pour leur utilisation en tant que medicament
FR3163835B1 (fr) 2024-06-26 2026-06-26 Rest Therapeutics Derives de fluoroethylnormemantine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
BRPI0516112A (pt) * 2004-10-15 2008-08-26 Janssen Pharmaceutica Nv métodos para neuroproteção
US20090118376A1 (en) * 2007-11-02 2009-05-07 Ru-Band Lu Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20120115943A1 (en) * 2008-10-01 2012-05-10 National Taiwan University Composition and method for neuroprotection against excitotoxic injury
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
FR3006193B1 (fr) * 2013-05-29 2015-06-19 Holis Technologies Nouveaux composes chimiques derives de la memantine et susceptibles de se fixer sur les recepteurs de n-methyl-d-aspartate (nmda)
FR3050732B1 (fr) 2016-05-02 2019-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux derives de phosphinolactones et leurs utilisations pharmaceutiques
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
WO2020232246A1 (en) * 2019-05-15 2020-11-19 The Trustees Of Columbia University In The City Of New York Compositions and methods against stress-induced affective disorders and their associated symptoms

Similar Documents

Publication Publication Date Title
RU2368604C2 (ru) Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина
EP2813498B1 (en) Compounds for Alzheimer's disease
JP2006504656A5 (cg-RX-API-DMAC7.html)
US9034871B2 (en) Compounds for Alzheimer's disease
US20120225845A1 (en) Compounds for diseases and disorders
JP2005506308A5 (cg-RX-API-DMAC7.html)
JP2025004090A (ja) 統合失調症を治療するための2-((1-(2(4-フルオロフェニル)-2-オキソエチル)ピペリジン-4-イル)メチル)イソインドリン-1-オン
US20080188524A1 (en) Methods of treating pain
AU2007214128B2 (en) Use of KCNQ-openers for treating or reducing the symptoms of schizophrenia
EP1641461B1 (fr) Association d'un antagoniste ou agoniste inverse du recepteur h3 de l'histamine avec un anti-psychotique ou un antidepresseur et son utilisation pour preparer un medicament prevenant des effets indesirables de medicaments psychotropes
JP2022513030A (ja) ヒストン脱アセチル化酵素6阻害剤を含む薬学的組成物
JP2022137234A (ja) 神経変性疾患の予防及び/又は治療剤
AU2008222890B2 (en) Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
JP7309824B2 (ja) 不安障害を治療するための(2S)-1-[4-(3,4-ジクロロフェニル)ピペリジン-1-イル]-3-[2-(5-メチル-1,3,4-オキサジアゾール-2-イル)ベンゾ[b]フラン-4-イルオキシ]プロパン-2-オールまたはその代謝産物
WO2013161993A1 (ja) トランス-2-デセン酸誘導体及びこれを含有する医薬
KR930006009A (ko) 4-[4-[4-(4-히드록시페닐)-1-피페라지닐]페닐]-5-메틸-3h-1,2,4-트리아졸-3-온 유도체
JP2005501834A5 (cg-RX-API-DMAC7.html)
US7470708B2 (en) Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies
JP6025886B2 (ja) 慢性疼痛治療剤
KR101503782B1 (ko) 신경 세포사 억제제
TW201208683A (en) Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
JPH11335286A (ja) ドーパミン拮抗薬の効果増強剤
TH2101008237A (th) อนุพันธ์เตตระไฮโดรไอโซควิโนลีนที่แทนที่ในฐานะเป็นสารดัดแปลงอัลโลสเตอริกด้านบวกของ d1
JP2008516898A5 (cg-RX-API-DMAC7.html)
HK1129593A1 (en) Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia